Akari Therapeutics Plc Forecast and Stock Analysis
Technical AKTX stock analysis for Wednesday May 22, 2019.
|Price to book||USD 13.40|
|Next Earnings Date||2019-08-19|
Akari Therapeutics Plc fell by -4.74% in the last day ( Wednesday, 22nd May 2019 ) from $2.53 to $2.41 and has now fallen 7 days in a row. During day the stock fluctuated 8.33% from a day low at $2.40 to a day high of $2.60. The price has fallen in 9 of the last 10 days and is down by -28.27% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -92 291 shares and in total 72 802 shares bought and sold for approximately $175 453.00.
- 30 day high of the AKTX stock price was $5.04 and low was $2.40.
- 90 day high was $9.20 and low was $1.76.
- 52 week high for the Akari Therapeutics Plc - $9.20 and low - $1.56.
Akari Therapeutics Plc has broken the very wide and strong rising short-term trend down. This signalize a slower rising rate, but may also be an early warning about a possible trend shift. Due to trend being broken there will now be resistance at the bottom line of the trend at $2.47. A reaction back to this level may hold a second chance to get out before further falls.
There are few to none technical positive signals at the moment. Akari Therapeutics Plc holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $2.77 and $3.29. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Friday May 03, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Relative Strength Index (RSI)
RSI14 is 6 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.
Support & Resistance
On the downside, the stock finds support just below today's level from accumulated volume at $1.83 and $1.83.
There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Akari Therapeutics Plc finds support just below today's level at $1.83. If this is broken, then the next support from accumulated volume will be at $1.83 and $1.81.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.20 between high and low, or 8.33%. For the last week the stock has had a daily average volatility of 7.18%.
Akari Therapeutics Plc is overbought on RSI14 (6). Some stocks may go long and hard while being overbought on RSI, but overbought increases the general risk as higher volatility could be expected, and at some level the stock will have a reaction back to gain new strength.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
7.18 %Average volatility
Very Low Low Medium High Very High
The Akari Therapeutics Plc stock holds several negative signals and despite the positive trend we believe Akari Therapeutics Plc will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
|Golden Star Signal|
Get competitive edge
The signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives a very good return. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day!
Get access to Golden Star list now
|AKTX $2.41 ($-0.12 -4.74%)|
AKTX is down $0.12 today, but where's it headed in 2019?
|Zacks Investment Research is releasing its prediction for AKTX based on the 1-3 month system that more than doubles the S&P 500.
This report is free today for StockInvest.us readers.
Click here – the AKTX analysis is free »
From Our Blog
- Trading With Moving Average
- Pivot Points
- Accumulated Volume - Support and Resistance
- Volume - The Indicator You Really Need to Know
- We Give Back!
- Better Buy: Amazon vs. Facebook
- Better Buy: Apple vs. Microsoft
- Relative Strength Index (RSI)
- How to Lose Money When Trading: Part 2
- How to Lose Money When Trading: A Trader is Born
- Our 2017 Christmas Donation
- The Golden Star
- Announcing Partnership With CityFALCON
- Why correct moving average matters
- NASDAQ down -4.17%. Our portfolio is up +8.56%
- New Feature Added: Golden Star Signal
- Pick a Winner With StockInvest.us